These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 33377126)

  • 1. Stimulation of B Cell Immunity in Flavivirus-Naive Individuals by the Tetravalent Live Attenuated Dengue Vaccine TV003.
    Tu HA; Nivarthi UK; Graham NR; Eisenhauer P; Delacruz MJ; Pierce KK; Whitehead SS; Boyson JE; Botten JW; Kirkpatrick BD; Durbin AP; deSilva AM; Diehl SA
    Cell Rep Med; 2020 Dec; 1(9):100155. PubMed ID: 33377126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.
    Whitehead SS; Durbin AP; Pierce KK; Elwood D; McElvany BD; Fraser EA; Carmolli MP; Tibery CM; Hynes NA; Jo M; Lovchik JM; Larsson CJ; Doty EA; Dickson DM; Luke CJ; Subbarao K; Diehl SA; Kirkpatrick BD
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005584. PubMed ID: 28481883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults.
    Kirkpatrick BD; Durbin AP; Pierce KK; Carmolli MP; Tibery CM; Grier PL; Hynes N; Diehl SA; Elwood D; Jarvis AP; Sabundayo BP; Lyon CE; Larsson CJ; Jo M; Lovchik JM; Luke CJ; Walsh MC; Fraser EA; Subbarao K; Whitehead SS
    J Infect Dis; 2015 Sep; 212(5):702-10. PubMed ID: 25801652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans.
    Nivarthi UK; Swanstrom J; Delacruz MJ; Patel B; Durbin AP; Whitehead SS; Kirkpatrick BD; Pierce KK; Diehl SA; Katzelnick L; Baric RS; de Silva AM
    Nat Commun; 2021 Feb; 12(1):1102. PubMed ID: 33597521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissecting Antibodies Induced by a Chimeric Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-Exposed Individuals.
    Henein S; Swanstrom J; Byers AM; Moser JM; Shaik SF; Bonaparte M; Jackson N; Guy B; Baric R; de Silva AM
    J Infect Dis; 2017 Feb; 215(3):351-358. PubMed ID: 27932620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.
    Nivarthi UK; Kose N; Sapparapu G; Widman D; Gallichotte E; Pfaff JM; Doranz BJ; Weiskopf D; Sette A; Durbin AP; Whitehead SS; Baric R; Crowe JE; de Silva AM
    J Virol; 2017 Mar; 91(5):. PubMed ID: 28031369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial.
    Kallas EG; Precioso AR; Palacios R; Thomé B; Braga PE; Vanni T; Campos LMA; Ferrari L; Mondini G; da Graça Salomão M; da Silva A; Espinola HM; do Prado Santos J; Santos CLS; Timenetsky MDCST; Miraglia JL; Gallina NMF; Weiskopf D; Sette A; Goulart R; Salles RT; Maestri A; Sallum AME; Farhat SCL; Sakita NK; Ferreira JCOA; Silveira CGT; Costa PR; Raw I; Whitehead SS; Durbin AP; Kalil J
    Lancet Infect Dis; 2020 Jul; 20(7):839-850. PubMed ID: 32220283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent Plasmablast-Derived Antibodies Elicited by the National Institutes of Health Dengue Vaccine.
    Magnani DM; Silveira CGT; Ricciardi MJ; Gonzalez-Nieto L; Pedreño-Lopez N; Bailey VK; Gutman MJ; Maxwell HS; Domingues A; Costa PR; Ferrari L; Goulart R; Martins MA; Martinez-Navio JM; Fuchs SP; Kalil J; Timenetsky MDC; Wrammert J; Whitehead SS; Burton DR; Desrosiers RC; Kallas EG; Watkins DI
    J Virol; 2017 Nov; 91(22):. PubMed ID: 28878078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the Type-Specific and Cross-Reactive B-Cell Responses Elicited by a Live-Attenuated Tetravalent Dengue Vaccine.
    Michlmayr D; Andrade P; Nascimento EJM; Parker A; Narvekar P; Dean HJ; Harris E
    J Infect Dis; 2021 Feb; 223(2):247-257. PubMed ID: 32572472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?
    Whitehead SS
    Expert Rev Vaccines; 2016; 15(4):509-17. PubMed ID: 26559731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adults.
    Russell KL; Rupp RE; Morales-Ramirez JO; Diaz-Perez C; Andrews CP; Lee AW; Finn TS; Cox KS; Falk Russell A; Schaller MM; Martin JC; Hyatt DM; Gozlan-Kelner S; Bili A; Coller BG
    Hum Vaccin Immunother; 2022 Nov; 18(5):2046960. PubMed ID: 35290152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial.
    George SL; Wong MA; Dube TJ; Boroughs KL; Stovall JL; Luy BE; Haller AA; Osorio JE; Eggemeyer LM; Irby-Moore S; Frey SE; Huang CY; Stinchcomb DT
    J Infect Dis; 2015 Oct; 212(7):1032-41. PubMed ID: 25791116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delineating the serotype-specific neutralizing antibody response to a live attenuated tetravalent dengue vaccine.
    Gromowski GD; Henein S; Kannadka CB; Barvir DA; Thomas SJ; de Silva AM; Jarman RG
    Vaccine; 2018 Apr; 36(18):2403-2410. PubMed ID: 29602701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model.
    Kirkpatrick BD; Whitehead SS; Pierce KK; Tibery CM; Grier PL; Hynes NA; Larsson CJ; Sabundayo BP; Talaat KR; Janiak A; Carmolli MP; Luke CJ; Diehl SA; Durbin AP
    Sci Transl Med; 2016 Mar; 8(330):330ra36. PubMed ID: 27089205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
    Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
    Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses.
    Wollner CJ; Richner M; Hassert MA; Pinto AK; Brien JD; Richner JM
    J Virol; 2021 May; 95(12):. PubMed ID: 33762420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T Cell Responses Induced by Attenuated Flavivirus Vaccination Are Specific and Show Limited Cross-Reactivity with Other Flavivirus Species.
    Grifoni A; Voic H; Dhanda SK; Kidd CK; Brien JD; Buus S; Stryhn A; Durbin AP; Whitehead S; Diehl SA; De Silva AD; Balmaseda A; Harris E; Weiskopf D; Sette A
    J Virol; 2020 May; 94(10):. PubMed ID: 32132233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Transcriptional Signatures of the Immune Response to a Live Attenuated Tetravalent Dengue Vaccine Candidate in Non-human Primates.
    Strouts FR; Popper SJ; Partidos CD; Stinchcomb DT; Osorio JE; Relman DA
    PLoS Negl Trop Dis; 2016 May; 10(5):e0004731. PubMed ID: 27214236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial.
    Durbin AP; Kirkpatrick BD; Pierce KK; Elwood D; Larsson CJ; Lindow JC; Tibery C; Sabundayo BP; Shaffer D; Talaat KR; Hynes NA; Wanionek K; Carmolli MP; Luke CJ; Murphy BR; Subbarao K; Whitehead SS
    J Infect Dis; 2013 Mar; 207(6):957-65. PubMed ID: 23329850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid Induction and Maintenance of Virus-Specific CD8
    Graham N; Eisenhauer P; Diehl SA; Pierce KK; Whitehead SS; Durbin AP; Kirkpatrick BD; Sette A; Weiskopf D; Boyson JE; Botten JW
    Front Immunol; 2020; 11():479. PubMed ID: 32265929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.